发明名称 |
Liquid Factor VIII Formulations |
摘要 |
The invention is directed to a liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule, a calcium salt in a concentration of more than 10 mM, and a saccharide and/or polyol in a concentration of at least 100 mM, wherein the formulation has a pH from 5.5-7.5. The invention furthermore provides a method for optimising a liquid formulation of coagulation Factor VIII, the method comprising the steps of: (i) Providing one or more liquid formulations comprising Factor VIII to be tested; (ii) Adding a protein denaturant to said liquid formulations, and incubating the resulting solutions for a predetermined period of time; (iii) Analysing the incubated solutions of (ii) for the presence of dissociated Factor VIII; and (iv) Selecting one or more formulation(s) having a desired low level of dissociated Factor VIII. |
申请公布号 |
US2016000884(A1) |
申请公布日期 |
2016.01.07 |
申请号 |
US201314420564 |
申请日期 |
2013.08.13 |
申请人 |
Novo Nordisk A/S |
发明人 |
Rischel Christian;Soerensen Hans Holmegaard;Jensen Michael Bech;Bjerg Thomas |
分类号 |
A61K38/37;C12Q1/58;C12Q1/56;A61K38/38;C07K19/00 |
主分类号 |
A61K38/37 |
代理机构 |
|
代理人 |
|
主权项 |
1. A liquid, aqueous formulation of coagulation Factor VIII, comprising a Factor VIII molecule; a calcium salt in a concentration of more than 10 mM; and a saccharide and/or polyol in a concentration of at least 100 mM; wherein the formulation has a pH from 5.5-7.5. |
地址 |
Bagsvaerd DK |